What is Wellinks?
Based in New Haven, Connecticut, Wellinks operates at the intersection of digital health and chronic disease management. The company provides a comprehensive, virtual-first COPD management system designed to extend care beyond the traditional clinical environment. By integrating virtual pulmonary rehabilitation, personalized health coaching, and real-time monitoring via connected devices and a proprietary smartphone application, Wellinks effectively addresses the high costs and accessibility barriers associated with COPD. Its platform is engineered to provide evidence-based care, empowering patients to manage their condition with greater autonomy and clinical support.
How much funding has Wellinks raised?
Wellinks has raised a total of $49.8M across 3 funding rounds:
Private Equity
$795K
Series C
$25M
Series B
$24M
Private Equity (2016): $795K, investors not publicly disclosed
Series C (2021): $25M led by The Morningside Group, Connecticut Innovations, Stonehenge Capital, HighCape Capital, and Benslie
Series B (2026): $24M supported by UMass Memorial Health and HighCape Capital
Key Investors in Wellinks
HighCape Capital
HighCape Capital is a growth equity fund established in 2013, focused on assisting innovative Life Sciences companies in their transition to successful organizations through hands-on operational and commercial support.
The Morningside Group
Founded in 1986, Morningside Group is a private equity and venture capital firm managed by entrepreneurial professionals with deep industry knowledge and a commitment to social responsibility.
Connecticut Innovations
Connecticut Innovations serves as the state's strategic venture capital arm, providing equity, debt financing, and guidance to help bioscience and technology companies scale effectively.
What's next for Wellinks?
With this major enterprise-level funding, Wellinks is well-positioned to scale its operations and deepen its impact within the connected health ecosystem. The strategic capital will likely be deployed to enhance its digital infrastructure, expand its network of clinical partners, and refine its data-driven monitoring capabilities. As the healthcare industry continues to shift toward value-based care and remote patient management, Wellinks is poised to capture significant market share by providing scalable, cost-effective solutions that reduce hospital readmissions and improve the quality of life for patients with chronic respiratory conditions.
See full Wellinks company page
